אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.03 mg (equivalent: estradiol, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red; propylene glycol - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

קנדה - אנגלית - Health Canada

lupin pharma canada limited - estradiol (estradiol hemihydrate) - tablet - 0.5mg - estradiol (estradiol hemihydrate) 0.5mg - estrogens

קנדה - אנגלית - Health Canada

lupin pharma canada limited - estradiol (estradiol hemihydrate) - tablet - 1mg - estradiol (estradiol hemihydrate) 1mg - estrogens

קנדה - אנגלית - Health Canada

lupin pharma canada limited - estradiol (estradiol hemihydrate) - tablet - 2mg - estradiol (estradiol hemihydrate) 2mg - estrogens

קנדה - אנגלית - Health Canada

sandoz canada incorporated - estradiol (estradiol hemihydrate) - patch - 50mcg - estradiol (estradiol hemihydrate) 50mcg - estrogens

קנדה - אנגלית - Health Canada

sandoz canada incorporated - estradiol (estradiol hemihydrate) - patch - 75mcg - estradiol (estradiol hemihydrate) 75mcg - estrogens

קנדה - אנגלית - Health Canada

sandoz canada incorporated - estradiol (estradiol hemihydrate) - patch - 100mcg - estradiol (estradiol hemihydrate) 100mcg - estrogens

ארצות הברית - אנגלית - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - estradiol/norethindrone acetate tablets are indicated for:   limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol/norethindrone acetate tablets are contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding [see warnings and precautions (5.2)] - breast cancer or history of breast cancer [see warnings and precautions (5.2)] - estrogen-dependent neoplasia [see warnings and precautions (5.2)] - active dvt, pe, or history of these conditions [see warnings and precautions (5.1)] - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions [see warnings and precauti

ארצות הברית - אנגלית - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.025 mg in 1 d - estradiol transdermal system (twice-weekly) is indicated for:       when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products.       when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol transdermal system (twice-weekly) is contraindicated in women with any of the following conditions: estradiol transdermal system (twice-weekly) is not indicated for use in pregnancy. there are no data with the use of estradiol transdermal system (twice-weekly) in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregna